Related Experiment Video

Updated: Dec 25, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K

[Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia]

Ying Zhao1, Yuan-Yuan Yang1, Ya-Wei DU1

  • 1Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Beijing 100700, China.

Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
|April 3, 2020
PubMed

Insights

Berberine effectively treats dyslipidemia by improving lipid profiles, including reducing total cholesterol (TC) and triglycerides (TG). This natural compound demonstrates good safety, with no significant increase in adverse events compared to controls.

Area of Science:

  • Cardiovascular Pharmacology
  • Natural Product Therapeutics
  • Evidence-Based Medicine

Background:

  • Dyslipidemia poses a significant risk factor for cardiovascular diseases.
  • Current lipid-lowering drugs have limitations and potential side effects.
  • Berberine, a natural alkaloid, has shown potential in managing lipid metabolism.

Purpose of the Study:

  • To systematically review and meta-analyze the clinical efficacy and safety of berberine for dyslipidemia.
  • To assess berberine's impact on lipid profiles (TC, TG, LDL-C, HDL-C) and adverse events.

Main Methods:

  • Comprehensive literature search across multiple databases (PubMed, Embase, Cochrane, etc.) up to January 2019.
  • Inclusion of 25 randomized controlled trials (RCTs) involving 3,042 patients.
  • Meta-analysis using RevMan 5.3 software, with subgroup analyses for interventions.

Main Results:

  • Berberine, alone or with conventional drugs, significantly reduced total cholesterol (TC), triglycerides (TG), and LDL-C.
  • Berberine significantly increased HDL-C levels compared to control groups.
  • No statistically significant difference in adverse event incidence was observed; no severe adverse effects were reported.

Conclusions:

  • Berberine demonstrates significant efficacy and a favorable safety profile in managing dyslipidemia.
  • High heterogeneity and low methodological quality of included trials necessitate further validation.
  • High-quality, large-scale, multi-center clinical trials are recommended to confirm these findings.

Keywords:
Meta-analysisberberinedyslipidemiaefficacysafetysystematic review

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
268
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
509
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
125
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
152
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
142